Related references
Note: Only part of the references are listed.Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients
Gerwin Huls et al.
BLOOD (2019)
Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience
Chezi Ganzel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
Marcos de Lima et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
M. Jongen-Lavrencic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
Felicitas Thol et al.
BLOOD (2018)
Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.
Tapan M. Kadia et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant
Brenda M. Sandmaier et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse
TaeHyung Kim et al.
BLOOD (2018)
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission
Sumithira Vasu et al.
BLOOD ADVANCES (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia
Farhad Ravandi et al.
CANCER (2017)
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)
W. Blum et al.
LEUKEMIA (2017)
Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study
Arnaud Pigneux et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bart L. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
Hagop M. Kantarjian et al.
LANCET ONCOLOGY (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Current Use and Trends in Hematopoietic Cell Transplantation in the United States
Anita D'Souza et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001
Geoffrey L. Uy et al.
BLOOD ADVANCES (2017)
Acute myeloid leukemia-Major progress over four decades and glimpses into the future
Hagop Kantarjian
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials
Armin Rashidi et al.
BLOOD (2016)
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission
Andrew M. Brunner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia
Gail J. Roboz et al.
FUTURE ONCOLOGY (2016)
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
Daisuke Araki et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Assessment of Minimal Residual Disease in Standard-Risk AML
A. Ivey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Iskra Pusic et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial
Nicolas Boissel et al.
HAEMATOLOGICA (2015)
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial
Nicolas Boissel et al.
HAEMATOLOGICA (2015)
Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
Yi-Bin Chen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
Oliver C. Goodyear et al.
BLOOD (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne et al.
LANCET (2012)
Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin
Hugo F. Fernandez et al.
BLOOD (2011)
Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System
Christoph Roellig et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation
John R. Wingard et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
Michael Grovdal et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial
Mats Brune et al.
BLOOD (2006)
Prognostic index for adult patients with acute myeloid leukemia in first relapse
DA Breems et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia:: an Eastern Cooperative Oncology Group Trial (E5483)
C Robles et al.
LEUKEMIA (2000)